Weeks-long extracorporeal blood oxygenation
Membrane oxygenator circuits that exchange gas with flowing blood for weeks without clotting, hemolysis or heavy anticoagulation.
State of the art
Clinical ECMO supports adults and neonates for weeks; pumpless low-resistance umbilical oxygenator circuits sustained fetal lambs for up to four weeks (CHOP EXTEND data presented to FDA, 2023).
- Blood-surface contact activates coagulation, so runs depend on anticoagulation that causes bleeding in fragile patients
- Oxygenator plasma leakage and fiber fouling limit single-circuit life
- Hemolysis and platelet consumption scale with pump shear and circuit length
Who’s working on it
- Alan FlakeResearcherChildren's Hospital of Philadelphia
Built the EXTEND extrauterine support system and is a named inventor on CHOP and Vitara pumpless neonatal oxygenator filings published in 2026
- Vitara BiomedicalStartup
CHOP spin-out that raised a 50 million dollar Series B in November 2024 (Sands Capital, GV, Khosla) to take its oxygenation circuit to first-in-human
- George MychaliskaResearcherUniversity of Michigan
Lead author on the nitric-oxide surface anticoagulation circuit that supported premature lambs for a week with no systemic anticoagulant (Pediatric Research, 2023)
- Robert BartlettResearcherUniversity of Michigan
Founder of clinical ECMO; his group's decades of artificial-placenta work underpin the current heparin-free circuit designs
- GetingeCompany
Maker of the Cardiohelp and Cardiosave systems; in 2025 it ended surgical perfusion production to reallocate R and D into ECMO and transplant care
- MedtronicCompany
Launched the all-in-one VitalFlow ECMO system in September 2024, adding competition in the US extracorporeal support market
- EurosetsCompany
Sells heparin-free phosphorylcholine-coated A.L.ONE oxygenator modules rated for 30-day ECMO runs in adults, children and newborns
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Truly non-thrombogenic surface coatings validated over multi-week large-animal runs without systemic heparin | $$ $10M – $100M |
| engineering | Miniaturized low-prime pumpless oxygenators sized for sub-kilogram patients | $$ $10M – $100M |
Depends on
A root node: no prerequisites modeled.